Sonnet biotherapeutics appoints richard kenney as chief medical officer and manuel dafonseca as head of clinical operations

Princeton, nj / accesswire / march 22, 2021 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of richard kenney, m.d. as chief medical officer and manuel dafonseca, as head of clinical operations, effective march 22, 2021.
SONN Ratings Summary
SONN Quant Ranking